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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the eBects of vitamin and mineral supplementation on cognitive function in cognitively healthy people in mid life.
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid life (Protocol)









Cochrane Database of Systematic Reviews
B A C K G R O U N D
Description of the condition
Cognitive health, mild cognitive impairment and dementia
Cognitively healthy or successful cognitive ageing can be
defined as "not just the absence of cognitive impairment, but
the development and preservation of the multi-dimensional
cognitive structure that allows the older adult to maintain social
connectedness, and ongoing sense of purpose, and the abilities
to function independently, to permit functional recovery from
illness and injury, and to cope with residual cognitive deficits"
but there is no broad consensus on a definition yet (Depp 2012;
Hendrie 2006). Successful cognitive ageing is distinct from mild
cognitive impairment (MCI) and dementia. Dementia is a syndrome
of cognitive and functional decline that is usually progressive.
Although most commonly associated with forgetfulness, memory
is not the only function that is aBected. Other higher cortical
functions such as orientation, comprehension, learning, language
and judgement are oLen impaired.
In most cases, the onset of dementia is gradual. In the early stages
of the illness, cognitive deficits are relatively mild, but still aBect
the ability to perform some normal daily activities. As the syndrome
progresses, those aBected become increasingly dependent on
others for all activities of daily living. Prior to the onset of the
disease, there is usually a stage of mild cognitive impairment
(MCI) when cognitive deficits beyond those of normal ageing are
detectable, but ordinary activities are not significantly aBected.
Types of MCI and dementia
There are numerous definitions of MCI, with diBerent focus (e.g.,
neuropsychological impairment such as memory versus non-
memory; Matthews 2007), prevalence (Stephan 2007); and risk of
progression to dementia (Matthews 2008). Further subdivisions
can be made depending on the suspected underlying cause of
cognitive deficits and this has lead to the distinction between
MCI due to Alzheimer's disease and MCI due to vascular disease
(termed 'vascular cognitive impairment no dementia': VCIND).
Moreover, attempts have been made to develop new criteria
to capture early preclinical states including, for example, pre-
MCI that captures individuals with impaired executive function
and language, higher apathy scores, and lower leL hippocampal
volumes compared to normal controls (Duara 2011). Still, there
is no standardised definition of MCI accepted for use in clinical
trials (Christa Maree Stephan 2013), but adaptations of the criteria
suggested by Petersen 1999 are commonly used.
Subtypes of dementia are distinguished by the underlying
pathology. The four most common subtypes are Alzheimer's
disease dementia (AD), accounting for an estimated 60% to 70%
of all dementia cases; vascular dementia (VaD); dementia with
Lewy Bodies (DLB); and frontotemporal dementia (FTD). Accurate
diagnosis of the subtypes may be diBicult. Mixed pathology is
common, with more than 80% of cases having some features
of Alzheimer’s disease (Jellinger 2006; World Health Organization
2012). However, the proportion of dementia attributable to
Alzheimer’s disease reduces with age (Savva 2009).
Prevalence of MCI and dementia
In the UK Medical Research Council's population-based Cognitive
Function and Ageing Study (CFAS), when 18 diBerent definitions
of MCI were mapped the range of prevalence estimates was found
to be variable (0.1% to 42.0%), and conversion rates to dementia
generally low (Stephan 2007). However, prevalence and conversion
rates in specialist settings have been reported to be higher than
population-based studies (adjusted conversion rate from MCI to
dementia 9.6% versus 4.9%; Mitchell 2009).
The risk of dementia increases with age; according to a World
Health Organization (WHO) report, only 2% to 10% of cases
start before the age of 65 (World Health Organization 2012).
The same report estimated that there were 35.6 million people
with dementia in the world in 2010, and that this figure would
double every 20 years to reach 65.7 million in 2030 (World Health
Organization 2012). However, there is a degree of uncertainty about
the expected increase in prevalence of dementia. Recent CFAS
research by Matthews 2013, and by Christensen 2013 on work in
Denmark suggests that age-specific prevalence of dementia may
be reducing in developed countries which supports the possibility
that there may be modifiable risk factors. Nevertheless, because of
population ageing, the overall prevalence continues to rise.
Risk factors
Many dementia syndromes are known to have a long preclinical
phase making it important to identify exposure to putative risk
factors in mid life, before neuropathological features of various
dementia subtypes start to develop in the brain (Rusanen 2011).
Generally, risk factors of dementia can be divided into modifiable
and non-modifiable factors: the non-modifiable risk factors include
age, genetic factors, family history, gender (females are at
higher risk), and Down syndrome. The modifiable factors include
smoking (both current and past smoking), high cholesterol, stroke,
hypertension, lack of physical activity, diabetes mellitus, obesity,
and low educational level. Among the non-modifiable risk factors,
age is found to be the most significant one. It has been indicated
that, in people who are older than 65 years, the risk of AD (the most
typical cause of dementia) doubles every five years (Launer 1999;
McCullagh 2001; van den Berg 2012; van der Flier 2005). A pooled
analysis of four prospective studies in Europe has revealed that the
incidence rate of AD among people aged 90 and over was 63.5/1000
person-year (Launer 1999).
Although age is the strongest risk factor, other risk factors for
AD have been identified. Genetics plays a major role in early
onset AD, but a lesser role in the much commoner late onset
disease. Epidemiological evidence (World Alzheimer Report 2014)
suggests that AD shares many risk factors with vascular disease,
including diabetes, midlife obesity, midlife hypertension, smoking
and physical inactivity (World Health Organization 2012). The
possible mechanism of cognitive decline in late life is thought to be
due to decreasing co-ordination between diBerent cortical regions
which work for the higher level cognitive functions. Such changes in
brain function may have a role in some physiological disorders like
hypertension, for instance, which is also a risk factor for cognitive
decline (Bishop 2010; O'Sullivan 2001).
At present there is no cure for any subtype of dementia, but
the identification and targeting of modifiable risk factors may
oBer opportunities to modify its onset and course. The World
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Alzheimer Report 2014 suggests that good nutrition, education
and social and mental stimulation may be protective. There is
evidence that vitamins such as vitamin B12 and folate will lower
homocysteine which is neurotoxic (see Appendix 1: Vitamins). Also,
there is evidence that vitamin D might have protective actions and
is being proposed for further investigation in the treatment of AD
(Annweiler 2012; Llewellyn 2010). A recent randomised controlled
trial (RCT) has shown that Vitamin E might slow down functional
decline in people with AD (Dysken 2014). Many minerals might
have antioxidant properties and may be beneficial in protecting
against oxidative stress and free radical damage (see Appendix 1:
Minerals). Hence, an evaluation of the role of vitamins and minerals
as protective and preventive agents in cognitive impairment is
highly warranted. Consequently, it is necessary to evaluate the
potentially eBective vitamin or mineral (or vitamin and mineral)
supplements in persons at either mid life (this review), late life (Al-
Assaf 2015), or with MCI (Abraham 2015).
Description of the intervention
This review focusses on RCTs investigating the eBect of vitamins
and minerals on cognitive functioning. Vitamins are organic
compounds that are essential for the normal physiological process
in the body and play important roles in growth and development
(Kennedy 2011). Minerals are inorganic elements and are nutrients
that are needed by the body to grow and develop normally (Centers
for Disease Control and Prevention 2014). Most of these essential
nutrients are available naturally through diet. Dietary supplements
are any consumed products that aim to supplement the diet and
provide additional nutrients to the ones obtained by regular diet.
How the intervention might work
Studies have revealed that vitamins and minerals have important
roles in the physiology of the human body at cellular and at tissue
levels. Putative biological mechanisms for each are summarised
briefly in Appendix 1.
There is a complex array of micronutrients which protect the brain
in a variety of ways, from protecting against damaging oxygen
free radicals to neurogenesis, gene expression, and enzyme and
receptor control (Powell 2000). Failure of these important systems
appears to be implicated in the occurrence of neural damage and
might be neutralised by antioxidant micronutrients (van der SchaL
2013). Therefore, adequate vitamin and mineral levels in the body
might possibly enhance cognitive function.
Oxidative stress has been shown to be a damaging process
leading to an imbalance between oxygen free radicals, and the
anti-oxidative defences of, and repair of oxidative damage to,
proteins, lipids, RNA, and DNA (Halliwell 1992; Halliwell 1999;
Tabet 2001; Tabet 2002). In addition the central nervous system
(CNS) contains high levels of unsaturated fatty acids that are
substrates for peroxidation reactions (Ogawa 1994). An important
defence mechanism in the brain involves enzymatic antioxidants
which, if mediated through the supplementation of micronutrients,
may replenish the brain with synthetic antioxidants providing
a therapeutic approach to reduce oxidative stress (Reiter 1995).
This may be a useful adjunct in modifying risk factors in the
pathogenesis of neurodegenerative disorders (Packer 1997).
Vitamins and minerals are involved in thousands of intracellular
and extracellular mechanisms in the CNS. Exact functions diBer
according to the type of molecules and compounds involved.
These activities can be classified into a number of roles that
support homeostasis and create an ideal environment for neuronal
health. This may help maintain brain and cognitive reserve which
in turn may impact the rate of decline of those most at risk of
dementia. Brain and cognitive reserve, developed early in life and
consolidated in mid life, may buBer the expression of symptoms of
dementia in the presence of neurodegenerative disease (Casserly
2004).
Vitamins:
Vitamin A may be involved in the stabilisation of beta amyloid
fibrils (Ono 2012). Vitamin D has been implicated as a precursor of
hormones required for calcium and phosphorus metabolism and
also potentially has a role in cognition in older adults (Przybelski
2007). Vitamin E is an antioxidant and is involved in free radical
chain reactions; it provides protection against free radical damage
(Farina 2012; Takatsu 2009). B vitamins—notably B12 and folic acid
—have a role in energy production and metabolism within the
CNS. B vitamins have also been implicated in the production of
nucleic acids and production and maintenance of myelin, essential
for good neuronal health (Kühnast 2013; Osiezagha 2013; Pawlak
2014; Powers 2003; World Alzheimer Report 2014). Several clinical
studies evaluated eBect of vitamins on cognition. For example, a
double-blind placebo RCT showed that 8 weeks' supplementation
of multivitamin enhanced contextual recognition memory (a test
of episodic memory) in older age men who are at risk of cognitive
decline (Harris 2012). They indicated that contextual recognition
memory is usually the first cognitive function to be damaged in the
development of cognitive decline, mild cognitive impairment and
Alzheimer’s disease (Harris 2012).
Minerals:
There are a number of minerals which are involved in neuronal
gene expression and the neuronal secretion of neurotransmitters
(Ozawa 2012; Rossom 2012). Selenium was found to have some
benefit in improving cognitive-cerebral function in older adults
post chromium supplementation (Krikorian 2010; Smorgon 2004).
Potassium, calcium, and magnesium were found to be protective
in a cohort of Japanese participants (Ozawa 2012). Selenium may
induce repair of DNA in damaged cells, and so limit growth of cancer
cells. Selenium is a critical component of the enzyme glutathione
peroxidase that detoxifies harmful molecules, making it especially
important for cancer protection. As an antioxidant, selenium has
been shown to protect the CNS and immune system from oxidative
damage by harmful free radicals (Berr 2012; Mehdi 2013; Smorgon
2004).
Why it is important to do this review
Braak 1991 and Serrano-Pozo 2011 described changes that occur
in mid life that justify interventions at an early stage. Shah 2012
found that "in participants in mid life with a mean age of 58
that β-Amyloid (Aβ), a vasoactive protein, and elevated blood
pressure (BP) levels are associated with Alzheimer disease (AD) and
possibly vascular dementia". Early interventions ultimately aim
at maintaining cognitive functioning, preventing cognitive decline
and dementia.
The prevalence and financial implications of dementia are such
that small eBects on cognitive decline or on the incidence of
dementia may have a large impact on healthcare costs and the
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overall burden of dementia. Robust assessments are needed of
the eBect size of interventions and of the ‘dose’ and duration of
intervention necessary to achieve an eBect.
For individuals, fear of cognitive decline and dementia may be
powerful motivators to seek preventive interventions. Nutritional
supplements and cognitive activities (e.g. computerised 'brain
training' games) in particular are subject to promotion by those
with commercial interests. It is important for people to know
whether time, eBort and money they might invest to prevent
cognitive decline is likely to be well spent. Information about
adverse eBects is also important. Although nutritional and
behavioural interventions are oLen perceived to be ‘low risk’,
they are not necessarily without the potential to cause harm. For
example, trials have found high doses of vitamin E to be associated
with higher rates of side eBects than placebo (Bjelakovic 2012;
Brigelius-Flohe 2007; Miller 2005).
O B J E C T I V E S
To evaluate the eBects of vitamin and mineral supplementation on
cognitive function in cognitively healthy people in mid life.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include in the review randomised or quasi-randomised
controlled trials, published or unpublished, reported in any
language. We will include studies involving both randomised and
non-randomised trial arms, but we will only consider results from
the former. We may include crossover studies, but we will extract
and analyse data from the first treatment period only. To be
considered, trials need to report outcomes at at least one time
point 12 weeks or more aLer randomisation. Trials in cognitively
healthy people with a duration as short as 12 weeks will typically be
investigating cognitive enhancement rather than maintenance of
cognitive function. We will include these trials in order to give a full
picture of the data, although it is recognized that the relationship
between short-term cognitive enhancement and maintenance of
cognitive function over longer periods of time is unclear.
Types of participants
The cognitive status of participants will be determined by the
trialists’ own definitions of ‘cognitively healthy’. These definitions
will be recorded.
Only trials using internationally accepted and validated
instruments to assess cognitive function or dementia status at
baseline will be included.
We will include trial populations of cognitively healthy people in
mid life, i.e. participants aged 40 to 65 without a dementia diagnosis
or cognitive impairment at baseline. (Mid life is defined for the
purposes of disease classification in DSM IV, 1994, as between 40
and 65; those older than 65 years will be classified as late life and
will be covered in a separate review (Al-Assaf 2015)).
Where studies clearly state the age of participants among their
inclusion criteria, this will be used as in the classification. If this
is not available, the median and range or mean and standard
deviation will be used to help place studies with a broad age range
into the most appropriate review category. For example a study
with an age range of 40 to 70, with a median of 50 years or less, will
be considered mid-life, whereas one with a median of 65 years or
more would likely be categorised as late life.
Regarding concomitant disease, studies are not required to include
blood tests.
We will contact trialists if further clarification is needed to
determine health status or age. If there is no response then clinical
experts in the respective review groups will classify the trials; or we
will list these as 'studies awaiting classification’.
Types of interventions
We will include studies comparing the eBects of the described
vitamin and mineral supplementation interventions with control
interventions that are not expected to have specific risk-modifying
eBects. The control arms would typically involve placebo or no
intervention/usual care. The minimum treatment duration is set
at 12 weeks. Experimental interventions may concern individual
or combination treatments with any of the supplements listed in
Appendix 1. Trials of vitamins or minerals given in combination
with other unrelated compounds (e.g. fatty acids, amino acids or
medications) will be excluded, unless the eBects of the vitamins and
minerals can be isolated. A trial evaluating the eBects of vitamin A
and C versus methionine would thus be excluded, whereas a trial
evaluating vitamin A and C with methionine versus methionine only
would be included. Only orally-administered supplements taken at
any dose will be included.
Types of outcome measures
Primary outcomes
Mean overall cognitive functioning measured with any
internationally accepted and validated measure: for example,
Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-
cog); The Mini Mental State Examination (MMSE); Repeatable
Battery for the Assessment of Neuropsychological Status (RBANS);
Cambridge Cognition Examination (CAMCOG).
The main time point of interest is end of trial, defined as the
time point with the longest follow-up duration as measured from
randomisation (see also section Data extraction and management).
Outcome data reported at other time points aLer randomisation
will be extracted and presented according to time points specified
in the Data synthesis section.
Secondary outcomes
Secondary outcomes are any internationally accepted and
validated measures of:
- specific cognitive functioning subdomain: episodic memory,
- specific cognitive functioning subdomain: executive functioning,
- specific cognitive functioning subdomain: speed of processing,
- quality of life, either generic or disease-specific,
- clinical global impression,
- functional performance,
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid life (Protocol)
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- incidence of MCI or all-cause dementia,
- number of participants experiencing one or more serious adverse
events (SAE),
- mortality.
Where studies include validated biomarkers (e.g. beta-amyloid or
tau in cerebrospinal fluid, structural MRI or amyloid imaging) as
well as cognitive outcomes, biomarker data will be extracted.
Outcomes to be included in the 'Summary of findings' table
Critical eBectiveness outcomes, to be addressed in the 'Summary
of findings' table, will include all outcomes related to cognitive
functioning, quality of life and mortality.
Search methods for identification of studies
Electronic searches
We will search ALOIS (www.medicine.ox.ac.uk/alois), the Cochrane
Dementia and Cognitive Improvement Group’s (CDCIG) specialised
register.
ALOIS is maintained by the Trials Search Co-ordinator for the
CDCIG, and contains studies that fall within the areas of dementia
prevention, dementia treatment and management, and cognitive
enhancement in healthy elderly populations. The studies are
identified through:
1. Monthly searches of a number of major healthcare databases:
MEDLINE, EMBASE, CINAHL, PsycINFO and LILACS;
2. Monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan's Trial Register); the WHO portal (which covers
ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register;
the German Clinical Trials Register; the Iranian Registry of
Clinical Trials and the Netherlands National Trials Register, plus
others);
3. Quarterly search of The Cochrane Library’s Central Register of
Controlled Trials (CENTRAL);
4. Six-monthly searches of a number of grey literature sources: ISI
Web of Knowledge Conference Proceedings; Index to Theses;
Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS on
the ALOIS website (www.medicine.ox.ac.uk/alois).
Details of the search strategies run in healthcare bibliographic
databases, used for the retrieval of reports of dementia,
cognitive improvement and cognitive enhancement trials, can
be viewed in the ‘methods used in reviews’ section within the
editorial information about the Cochrane Dementia and Cognitive
Improvement Group.
We will run additional searches in MEDLINE, EMBASE, PsycINFO,
CINAHL, ClinicalTrials.gov and the WHO Portal/ICTRP to ensure that
the searches for each suite of reviews is as comprehensive and
as up to date as possible to identify published, unpublished and
ongoing trials. The search strategy that will be used for the retrieval
of reports of trials from MEDLINE (via the Ovid SP platform) can be
seen in Appendix 2.
Searching other resources
We will screen reference lists of all included trials. In addition,
we will screen reference lists of recent systematic reviews, health
technology assessment reports and subject-specific guidelines
identified through www.guideline.gov. The search will be restricted
to those guidelines meeting NGC’s 2013 inclusion criteria published
in this year or later.
We will contact experts in the field and companies marketing
included interventions, in order to provide additional randomised
trial reports that are not identified by the search.
Data collection and analysis
We will use this protocol alongside instructions for data extraction,
quality assessment and statistical analyses, based on a generic
protocol generated by the editorial board of CDCIG, to guide
this and another 11 reviews on modifiable risk factors (see
Acknowledgements).
Selection of studies
If multiple reports describe the same trial, we will include all to
allow complete extraction of the trial details.
We will use crowdsourcing to screen the search results. Details
of this have been described here: http://www.medicine.ox.ac.uk/
alois/content/modifiable-risk-factors. In brief, teams of volunteers
will perform a ‘first assess’ on the search results. The volunteers
will be recruited through the author team’s institutions. They will
screen the results using an online tool developed for Cochrane
EMBASE project but tailored for this programme of work. The crowd
will decide, based on a reading of title and abstract, whether
the citation is describing a randomised or quasi-randomised trial,
irrespective of the citations topic. It is estimated that this will
remove 75% to 90% of results retrieved. The remaining results will
then be screened by the author team.
Data extraction and management
Two review authors, working independently, will extract trial
information using a standardised and piloted extraction method,
referring also to a guidance document. Discrepancies will be
resolved by discussion, or by the involvement of a third reviewer.
Where possible, we will extract (as a minimum) the following




• baseline age (range, median, mean)
• education (level and years of education)
• baseline cognitive function
• cognitive diagnostic status
• duration of cognitive symptoms, if any
• ethnicity
• Apo-E genotype
• diabetes mellitus (yes/no)
• physical activity (as defined by the trialists).
• smoking (never/ever)
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Intervention characteristics
• nature of the intervention; generic and trade name of
intervention
• description of the control condition
• duration of treatment
• dosage and frequency
• any concomitant treatments
• treatment adherence
Methodological characteristics
• trial design (individual or cluster randomisation; parallel-group,
factorial or crossover design)
• number of participants
• outcome measures used
• duration of follow-up as measured from randomisation
• duration of follow-up as measured from end of treatment
• source of financial support
• publication status
If outcome data is available at multiple time-points within a given
trial, we will group with cut-oBs to describe immediate results
(up to 12 weeks), short term (up to 1 year), medium term (1 to 2
years) and longer term results. For all-cause dementia or MCI, only
outcome data at 1 year of follow-up or longer will be considered and
therefore will be grouped as short-term (1 year), medium-term (up
to 2 years) and long-term (more than 2 years).
For dichotomous outcomes (such as incident dementia or
mortality), we will extract from each trial the number of participants
with each outcome.
For continuous outcomes, we will extract the number of
participants in whom the outcome was measured, and the mean
and standard deviation of the change from baseline for each
outcome at each time point. If change-from-baseline data are not
available, we will extract the mean value at each time point. When
necessary, means and measures of dispersion will be approximated
from figures in the reports.
For crossover trials, we will extract data on the first treatment
period only. Whenever possible, we will extract intention-to-
treat data i.e. analysing all patients according to the group
randomisation; if this is not available, then we will extract and
report data from available case analyses. If these data are both not
available, we will consider data from 'per protocol' analyses. We will
contact the authors if we cannot obtain the necessary data from the
trial report.
Assessment of risk of bias in included studies
ALer completion of a standardised training session provided by
AR, the risk of bias in each of the included trials will be assessed
independently by one member of the author team and one
experienced reviewer provided by the editorial team, using the
Cochrane's 'Risk of bias' tool (Higgins 2011). Disagreements will be
resolved by consensus. We will assess the risk of bias potentially
introduced by sub-optimal design choices with respect to sequence
generation, concealment of allocation, blinding of participants
and care-givers, blinded outcome assessment, selective outcome
reporting and incomplete outcome data, including the type of
statistical analyses used (true intention-to-treat versus other). The
general definitions that will be used are reported in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011);
the review-specific definitions are described in Appendix 3 and
are in part derived from a previously published systematic review
(Rutjes 2012).
Measures of treatment e:ect
The measure of treatment eBect for continuous outcomes will be an
eBect size (standardised mean diBerence), defined as the between-
group diBerence in mean values divided by the pooled standard
deviation (SD). The treatment eBect for dichotomous outcomes will
be expressed as a relative risk (RR).
Unit of analysis issues
If cluster randomised trials are included, we aim to extract outcome
data from analyses that take the eBect of clustering into account
(for example, an odds ratio with its confidence interval). When this
is not possible, we will attempt to account for clustering by reducing
the trial to its "eBective sample size", dividing the original sample
size by the design eBect, as described in Section 16.3.4 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011; Rao 1992).
Dealing with missing data
Missing data in the individual trials may put the study estimates
of eBects at a high risk of bias, and may lower the overall
quality of the evidence according to GRADE (Higgins 2011). We
will deal with missing data in our 'Risk of bias' assessments
and plan to evaluate attrition bias in stratified analyses of the
primary outcomes (Appendix 3). We will thus analyse the available
information and will not contact authors with a request to provide
missing information, nor will we impute missing data ourselves.
Assessment of heterogeneity
Heterogeneity will be examined in stratified analyses by trial,
participant and intervention characteristics, as outlined in
Appendix 3.
Assessment of reporting biases
If a suBicient number of trials (at least 10) can be identified, we
will use funnel plots with appropriate statistics to explore reporting
biases and other biases related to small study eBects (see also Data
synthesis).
Data synthesis
Whenever possible, we will use standard inverse-variance random-
eBects meta-analysis to combine outcome data across the trials
at end of trial (DerSimonian 1986); and, if possible, at least
one additional time point (see Primary outcomes and Data
extraction and management for definitions of time points). We
will visually inspect forest plots for the presence of heterogeneity
and will calculate the variance estimate tau2 as a measure of
between-trial heterogeneity (DerSimonian 1986). We pre-specify
a tau2 of 0.04 to represent low heterogeneity, 0.09 to represent
moderate heterogeneity, and 0.16 to represent high heterogeneity
between trials (Spiegelhalter 2004). The I2 statistic and the
corresponding Chi2 test will be depicted in addition (Higgins
2003), to facilitate readers more familiar with this statistic. I2
describes the percentage of variation across trials attributable
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to heterogeneity rather than chance, with values of 25%, 50%,
and 75% typically being interpreted as low, moderate, and high
between-trial heterogeneity. Tau2 will be preferred over I2 in the
interpretation of between-trial heterogeneity, as the interpretation
of I2 can be largely aBected by the precision of trials included in
the meta-analysis (Rücker 2008). If suBicient trials (around 10) can
be identified that contribute to the analyses of primary outcomes,
we will explore the association between trial size and treatment
eBects using funnel plots, where we plot eBect sizes on the x-axis
against their standard errors (SEs) on the y-axis (Moreno 2009;
Sterne 2001). Funnel plot asymmetry will be assessed with the
appropriate statistics for the metrics analysed (Higgins 2011). All P
values are 2-sided. Statistical analyses will likely be done in Review
Manager 5 (RevMan 2014); and in STATA, release 13 (StataCorp,
College Station, Texas).
Subgroup analysis and investigation of heterogeneity
If around 10 or more trials are identified that contribute to
the analyses of primary outcomes, we aim to perform stratified
analyses of the primary eBectiveness outcome, according to
the following trial characteristics: concealment of allocation,
blinding of patients, blinded outcome assessment, intention-to-
treat analysis, trial size, type of control intervention, duration
of treatment, and length of follow-up from randomisation
(Appendix 3). We will use univariable random-eBects meta-
regression models as tests of interaction between treatment eBect
and these characteristics (Thompson 1999). The cut-oB for trial
size, treatment duration and follow-up duration are described in
Appendix 3.
We will consider pooling interventions which have been postulated
to share a main mechanism of action in preventing development of
dementia. For example
• antioxidant properties—aBecting superoxide dismutase
(vitamin A, C, D, E, selenium)
• regulation/lowering levels of homocysteine: vitamins B12, folate
and B6
Knowledge of possible mechanisms of actions is evolving, and we
will consider other possible subgroups for data analysis as new
information arises during the development of the review.
In addition, we will be investigating other eBect modifiers,
related to the characteristics of participants. Apart from cognition
status and age of patients, we will also subgroup patients
into whether they are predisposed to risks of deficiency of
the vitamin and mineral supplement investigated (for example,
presence of malabsorptive diseases, malnutrition, comorbidities or
concomitant medications and ethnicity (Dawson-Hughes 2004).
Sensitivity analysis
For each review, we will perform one sensitivity analysis for the
primary eBectiveness outcome, including high-quality trials only.
High quality will be defined by the results of the stratified analyses,
based on the statistically significant (P less than 0.05) interaction
terms for methodological characteristics.
GRADE and summary of findings table
We will use GRADE to describe the quality of the overall body
of evidence for each outcome in the 'Summary of findings' table
(Higgins 2011; Guyatt 2008).
Quality is defined as the degree of confidence which can be
placed in the estimates of treatment benefits and harms. There
are four possible ratings: "high", "moderate", low" and "very low".
Rating evidence "high quality" implies that we are confident in
our estimate of the eBect, and further research is very unlikely to
change this. A rating of "very low" quality implies that we are very
uncertain about the obtained summary estimate of the eBect.
The GRADE approach rates evidence from RCTs which do not
have serious limitations as "high quality". However, several factors
can lead to the downgrading of the evidence to "moderate",
"low" or "very low". The degree of downgrading is determined
by the seriousness of these factors: study limitations (risk of
bias); inconsistency; indirectness of evidence; imprecision; and
publication bias (Higgins 2011; Guyatt 2008).
A C K N O W L E D G E M E N T S
This protocol is largely based on a general template constructed
for the development of a larger series of protocols and reviews
covered by a National Institute for Health Research (NIHR)
Systematic Reviews Programme Grant. The common protocol
covered four types of intervention, for which some evidence exists
that these may modify the risk of developing cognitive impairments
or dementia. These include vitamin and mineral supplements,
exercise, cognition, and dietary interventions. These interventions
will each be evaluated in three distinct populations: healthy mid-
life; healthy elderly; and those with mild cognitive impairment
(MCI). The general protocol was inspired by a generic protocol
approved by the Cochrane Musculoskeletal Group for another
series of reviews (da Costa 2012; Nüesch 2009; Reichenbach 2010;
Rutjes 2009a; Rutjes 2009b; Rutjes 2010).
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Appendix 1. Biological Plausibility of Vitamins and Minerals
 
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid life (Protocol)









Cochrane Database of Systematic Reviews







Carboxylic form of Vitamin A known as all-trans retinoic acid has been shown
to have memory restorative function and it may be attributed to its an-
ti-cholinesterase, anti-oxidative and anti-inflammatory potential (Sodhi 2013). Vit-
amin A and beta-carotene may also inhibit the formation, extension and destabilis-
ing effects of beta-amyloid fibrins. Plasma or cerebrospinal fluid concentrations of
vitamin A and beta-carotene have been reported to be lower in AD patients, and in-
creased Vit A/beta carotene concentrations have been clinically shown to slow the
progression of dementia (Ono 2012).
Vitamin D neuronal activity Vitamin D receptor (VDR) and 1, alpha-hydroxylase, the terminal calcitriol-activating
enzyme, are distributed throughout both the foetal and adult brain. This is thought
to play a role in brain development and critical brain functions (McCann 2008). Sig-
nificant correlation between serum 25(OH)D levels and cognitive scores were re-




Vitamin E consists of a group of tocopherols and tocotrienols. Apart from lipid an-
tioxidant activity, other functions include membrane stabilisation by forming com-
plexes with the products of lipid hydrolysis (Wang 2000). It has been shown that the
antioxidant and free radical scavenging activity of Vitamin E inhibits amyloid beta
protein induced neuronal cell death and may have implication in prevention and
treatment of Alzheimer’s dementia. (Behl 1992).
Vitamin K neuronal activity Vitamin K participates in the synthesis of sphingolipids. Sphingolipids participate
in important cellular events such as proliferation, differentiation, senescence and
cell-cell interactions. Sphingolipid metabolism has been linked to age-related cog-
nitive decline and neurodegenerative diseases such as Alzheimer's disease (Ferland
2012). A cross-sectional study found correlations between higher serum phylloqui-
none concentration and better cognitive scores in tests evaluating episodic verbal
memory among healthy older adults (Ferland 2013).
Thiamine
(Vitamin B1)
neuronal activity Thiamine is required as a cofactor in the cellular production of energy and enhances
normal neuronal activities (Osiezagha 2013). Rats with an episode of induced thi-
amine deficiency had cognitive, learning and memory impairments (Langlais 1995).
Riboflavin
(Vitamin B2)
neuronal activity Riboflavin (7,8-dimethyl-10-ribityl-isoalloxazine) is water soluble. Symptoms of neu-
rodegeneration and peripheral neuropathy in riboflavin deficiency have been doc-
umented in animal studies, but not observed in humans. Subclinical riboflavin de-
ficiency may contribute to increased concentrations of plasma homocysteine and
may be associated with increased risk of cardiovascular disease and impaired han-





Niacin is a water-soluble precursor cofactor essential for the formation of dozens
of enzymes. Niacin decreases atherosclerosis development mainly by reducing LDL
cholesterol. It also has modest HDL-cholesterol-raising and anti-inflammatory ef-
fects (Kühnast 2013).
Niacin deficiency causes pellagra. Its neuropsychiatric symptoms are similar to





phate (PLP) and pyri-
homocysteine;
neuronal activity
Vitamin B6 is a group of water-soluble compounds (vitamers). Pyridoxal 5' phos-
phate (PLP) and pyridoxamine 5' phosphate (PMP) are the active coenzyme forms of
vitamin B6 (ODS 2014).
Vitamin B6 has many important brain functions such as biosynthesis of neurotrans-
mitters (GABA, dopamine, noradrenaline, serotonin), receptor binding, macronu-
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trient metabolism, and gene expression. In a study looking at low plasma B6 levels
predicting cognitive decline and depression in at-risk individuals, low PLP status







Folate is a cofactor and promotes the remethylation of homocysteine -- an amino
acid that can induce DNA strand breakage, oxidative stress and apoptosis. Folate is
required for normal development of the nervous system, playing important roles
regulating neurogenesis and programmed cell death. Folate deficiency and its resul-
tant increase in homocysteine levels has been linked to several neurodegenerative










Vitamin B12 acts as a coenzyme in metabolism of amino acids and fatty acids re-
quired for the synthesis of nucleic acids, erythrocytes and in the maintenance of
myelin (Pawlak 2014). Lower vitamin B12 status has been associated with increased
rates of cognitive decline and dementia (Clarke 2007; O'Leary 2012).
Pantothenic Acid
(Vitamin B5)
energy; metabolism Pantothenic acid (PA) is a component of coenzyme A, an essential cofactor in fatty
acid oxidation, lipid elongation, and fatty acid synthesis (Kelly 2011). This may have
an indirect effect in cognition.
Biotin
(Vitamin H)
energy; metabolism Biotin is also known as Vitamin H and is part of the B complex group of vitamins.
They act as cofactors in carboxylase enzymes, fatty acid, and amino acid metabo-
lism. This may have an indirect effect in cognition.
Vitamin C anti-oxidant Vitamin C has antioxidant functions and is required for the synthesis of noradrena-
line from dopamine. It has been reported that Vitamin C levels have been lower than
controls in patients with senile dementia of Alzheimer’s type (Jeandel 1989). In a
longitudinal and cross-sectional study it was found that higher vitamin C levels were
associated with better memory performance (Perrig 1997).
Minerals    
Calcium neuronal activity Calcium ions regulate a number of physiological processes including neuronal gene
expression and the neuronal secretion of neurotransmitters (Dolphin 2012; Delage
2014 (accessed 21 September 2015)). Supplementation with calcium together with
vitamin D was found to have no significant association with incident cognitive im-
pairment (Rossom 2012).
Ozawa 2012 concluded that, in the general Japanese population, higher self-report-
ed dietary intakes of potassium, calcium, and magnesium reduced the risk of all-
cause dementia, especially Vascular Dementia (VaD). The proposed mechanism was
through the reduction of vascular risk factors.
Chromium energy production;
metabolism.
Chromium is needed for energy production and has been found to promote the ef-
fect of insulin involved in metabolism and storage of protein, carbohydrates and
lipids within the CNS (Institute of Medicine, FNB 2001; Ozawa 2012;Anderson 1997).
Chromium is involved in metabolism of nucleic acid, which is needed to build DNA,
the genetic material in cells; and promotes synthesis of cholesterol and fatty acids
needed for brain function. It may lower LDL cholesterol and triglyceride levels, raise
HDL cholesterol levels and reduce high blood pressure (Preuss 1997), hence may af-
fect vascular risk factors.
Insulin resistance is implicated in the pathophysiological changes associated with
Alzheimer's disease, and pharmaceutical treatments that overcome insulin resis-
tance improve memory function in subjects with mild cognitive impairment (MCI)
  (Continued)
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid life (Protocol)









Cochrane Database of Systematic Reviews
and early Alzheimer's disease. Chromium (Cr) supplementation improves glucose
disposal in patients with insulin resistance and diabetes. A double blind RCT sug-
gested that supplementation with Chromium picolinate can enhance cognitive in-
hibitory control and cerebral function in older adults at risk for neurodegeneration
(Krikorian 2010). An additional study reported a positive correlation between cogni-
tive function and serum chromium levels (Smorgon 2004).
Copper antioxidant Copper is a component of an antioxidant enzyme called superoxide dismutase
that protects cells from damage by harmful free radicals. Copper is necessary for a
healthy nerve system and taste sensitivity (Institute of Medicine, FNB 2001).
Copper may promote non-amyloidogenic processing of amyloid precursor protein
(APP) and thereby lower the Aβ production in cell culture systems, and it increas-
es lifetime and decreases soluble amyloid production in APP transgenic mice (Bor-
chardt 1999). In Alzheimer patients, a decline of Aβ levels in CSF is reported in adults
in the treatment group. (Kaden 2011).
Iodine neuronal develop-
ment and structure.
Iodine is needed for the synthesis of thyroid hormones which, in turn, are needed
for the myelination of the central nervous system. Iodine is necessary for the nor-
mal development of the brain. A deficiency of this mineral during critical periods of
development in gestation can lead to intellectual disability and neurodevelopmen-
tal problems (Bath 2013a). Positive association was found between maternal iodine
status and child IQ at age 8 years and reading ability at age 9 years (Bath 2013b).
Iron neuronal activity Iron is needed for development of oligodendrocytes and numerous enzymes that
synthesise neurotransmitters such as noradrenaline, serotonin, and dopamine. It
is important for production of the haemoglobin in red blood cells (Delage 2014 (ac-
cessed 21 September 2015); Institute of Medicine, FNB 2001). Regression analysis
showed that non-anaemic iron-deficient adolescent girls who received iron per-
formed better on a test of verbal learning and memory than girls in the control
group (Bruner 1996)
Magnesium energy, metabolism Magnesium is involved in hundreds of enzyme reactions, including protein synthe-
sis. It plays a role in energy production; can improve insulin sensitivity in diabetics;
helps regulate blood sugar level; and regulates neuro-muscular transmission.
Higher self-reported dietary intakes of potassium, calcium, and magnesium have
been reported to reduce the risk of all-cause dementia, especially VaD, in the gener-
al Japanese population (Ozawa 2012).
Manganese metabolism Manganese is needed to synthesise fatty acids and cholesterol, and metabolise car-
bohydrates and proteins. It is important for energy production. It promotes utilisa-
tion of other key nutrients like vitamin B1 (thiamine), biotin, choline, ascorbic acid,
and vitamin E (Delage 2014 (accessed 21 September 2015)).
Manganese is needed for glucose metabolism, which helps regulate blood glucose.
It is needed to make manganese superoxide dismutase (MnSOD), one of the key
antioxidants that protects cells from free radical damage, and so helps maintains
healthy nerves. It works synergistically with the B-complex vitamins to generate an
overall feeling of well-being (Institute of Medicine, FNB 2001).
Molybdenum metabolism Molybdenum promotes normal cell function; and functions as a cofactor for three
essential enzymes that play a vital role in carbohydrate metabolism, utilisation
of iron, sulphite detoxification, and uric acid formation (Delage 2014 (accessed 21




Phosphorus is needed for metabolism of carbohydrates and fats to produce energy
and is involved in the production of ATP required for growth and repair of cells and
tissues; needed to make cell membranes. It helps the body utilise the B-complex vi-
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tamins that support proper muscle and nerve function (Delage 2014 (accessed 21
September 2015); Institute of Medicine, FNB 2001).
Potassium nerve transmission. Potassium is involved in regulating nerve transmissions and muscle contractions. It
helps the body handle sodium and so reduces the risk of high blood pressure (Berr
2012). It has been found to lower the risk of stroke and ischaemic heart disease.
Potassium is needed for synthesis of protein from amino acids (Delage 2014 (ac-
cessed 21 September 2015); Institute of Medicine, FNB 2001).
Higher self-reported dietary intakes of potassium, calcium, and magnesium reduce
the risk of all-cause dementia, especially VaD, in the general Japanese population
(Ozawa 2012).
Selenium antioxidant. Selenium is an important antioxidant especially in combination with vitamin E,
in the central nervous system and other body tissues (Delage 2014 (accessed 21
September 2015); Institute of Medicine, FNB 2001; Mehdi 2013; Rahman 2007).
Low selenium levels were found to be associated with poorer cognitive function
(Berr 2012; Smorgon 2004). Supplementation with selenium has been associated
with improved overall health, reducing oxidative stress and reducing the risk of de-
mentia (Mehdi 2013).
Sodium neuronal activity Sodium is essential for regulating muscle contractions, nerve transmissions essen-
tial for normal CNS physiological mechanisms and homeostasis (Delage 2014 (ac-
cessed 21 September 2015); Institute of Medicine, FNB 2001).
Zinc anti-oxidant
neuronal activity
Zinc is a constituent of the antioxidant enzyme superoxide dismutase that helps re-
duce the harm from free radicals. Zinc regulates cell division and synthesis of ge-
netic cell DNA. It is essential for reproduction, repair, and normal growth within the
CNS (Delage 2014 (accessed 21 September 2015)).
Zinc is found in high levels in the brain where it performs catalytic, structural and
regulatory roles in cellular metabolism. Zinc is bound to proteins but free zinc is
present in synaptic vesicles and performs a role in neurotransmission mediated by
glutamate and gamma-aminobutyric acid (GABA). Short-term deficits of zinc have
been shown to impair certain measures of mental and neurological function while
long-term deficits of zinc, especially during gestation, result in malformation or
deficits in attention, learning, memory and neuropsychological behaviour (Institute
of Medicine, FNB 2001)
Zinc was found to be capable of reducing post-ischaemic injury to a variety of tis-
sues and organs through a mechanism that might involve the antagonism of cop-
per reactivity. Although the evidence for the antioxidant properties of zinc is com-
pelling, the mechanisms are still unclear (Powell 2000).
* Only orally-administered supplements taken at any dose for at least 12 weeks are considered. Supplements that combine vitamins
or minerals are eligible as well.
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Appendix 2. MEDLINE search strategy
1. exp *Vitamins/
2. exp *Minerals/
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10. "retinoic acid".ti,ab.
11. Vitamin A/

















































61. "Aged, 80 and over"/
62. Middle Aged/
63. Age Factors/
64. "mild cognitive impairment".ti,ab.






71. (nMCI or aMCI or mMCI or MCIa).ti,ab.
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98. 83 and 97
99. randomized controlled trial.pt.








108. exp Animals/ not humans.sh.
109. 107 not 108
110. 98 and 109 [all results]
111. *Vitamins/
112. *Cognition/
113. "Aged, 80 and over"/ or Aged/ or Middle Aged/
114. Mild Cognitive Impairment/
115. "mild cognitive impairment".ti,ab.
116. 113 or 114 or 115
117. 111 and 112 and 116
118. 99 or 100
119. 117 and 118 [results sent directly to author team]
120. 110 not 119 [results minus those sent directly to author team. These results will be screened by the 'crowd']
Appendix 3. Definitions of design, patient and intervention characteristics as applied in the stratified analyses






The guidance from the Cochrane Handbook for Systematic Reviews of
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Interventions (Higgins 2011) will be used to judge bias related to sequence generation and conceal-
ment of allocation using the two Cochrane 'Risk of bias' items. From these, the statistician will de-
rive a single variable to be used in the stratified analysis: allocation concealment will be judged at
low risk of bias if the investigators responsible for patient selection were unable to suspect before
allocation which treatment was next. Concealment will downgraded to high risk of bias if there is
evidence of inadequate sequence generation.
Blinding of patients and per-
sonnel (avoiding performance
bias)
Low risk of bias will be judged if:
- a credible sham procedure was used; or if a placebo supplement or pill was used that was re-
ported to be identical in appearance to the experimental intervention and the specific outcome or
group of outcomes is/are likely to be influenced by lack of blinding
- blinding is absent or suboptimal and the specific outcome, such as mortality, is not likely to be in-
fluenced by lack of blinding
Blinding of outcome assess-
ment (avoiding detection bias)
For self-reported/partner reported outcomes: 
Low risk of bias will be judged if:
- self-reported outcomes were assessed AND blinding of patients was considered adequate AND
there was no information to suggest that there was an investigator involved during the process of
outcome assessment; OR if blinding of investigators performing the outcome assessment was re-
ported AND an attempt to blind patients was reported.
For other outcomes: 





Low risk of bias will be judged if:
- at least 90% of the patients randomised were analysed AND the difference in percentage of par-
ticipants not analysed was 5% or lower across trial arms,
- for trials using imputations to handle missing data: the percentage of participants with missing
data did not exceed 20% AND the difference in percentage of participants with imputed data was
5% or lower across trial arms AND applied imputation methods were judged to be appropriate.
Multiple imputation techniques will be considered appropriate, simple methods such as "last ob-
servation carried forward" or "baseline carried forward" will be considered inappropriate.
For binary outcomes of rare events 
Low risk of bias will be judged if:
- the event rate is low (e.g. incidence of dementia) AND at least 95% of the patients randomised
were analysed AND there is no evidence of differential reasons for missing data that may alter the
estimate AND the rate of missing data does not exceed the expected event rates.
For binary outcomes of non-rare events 
Low risk of bias will be judged if:
- at least 90% of the patients randomised were analysed AND the difference in percentage of par-
ticipants not analysed was 5% or lower across trial arms AND there is no evidence of differential
reasons for missing data that may alter the estimate AND the rate of missing data does not exceed
the expected event rates.
Trial Size A large trial will be defined by a sample size calculation for the primary outcome.
Follow-up duration We will group studies according to these follow up cut-oBs to describe immediate results (up to 12
weeks), short-term (up to 1 year), medium-term (1 to 2 years) and longer-term results (more than 2
years) for cognitive outcomes.
For all cause dementia or MCI, the follow up durations will be grouped as short-term (1 year), medi-
um-term (up to 2 years) and long-term (more than 2 years).
Treatment related characteristics
Treatment duration The minimum treatment duration of 3 months is considered short term, 3 to 12 months as medium
term, and 12 months for long term.
  (Continued)
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Mechanisms of action of the
supplements**
Supplements postulated to share a main mechanism of action in preventing development of de-
mentia, including:
• Antioxidant properties - affecting superoxide dismutase (vitamin A, C, D, E, selenium)
• Regulation/lowering levels of homocysteine: vitamins B12, folate and B6
Dose of supplements High dose versus low dose supplements will be analysed according to previously reported cut-oBs
Participant-related characteristics
Cognition-related criteria No risk of deficiency vs at risk of deficiency for the type of vitamin and mineral supplement(s) in-
vestigated (e.g. presence of malabsorptive diseases, malnutrition, comorbidities or concomitant
medications, and ethnicity (Vitamin D))
  (Continued)
 
* The descriptions depicted in this Table are in addition to the guidance provided by Cochrane (Higgins 2011).
** Knowledge of possible mechanisms of actions is evolving, and we will consider other possible subgroups for data analysis as new
information arises during the development of the review.
C O N T R I B U T I O N S   O F   A U T H O R S
Completion of the protocol: David Denton, Rajesh Abraham, Anne Rutjes, Lee-Yee Chong, Aalya Al-Assaf, John Anderson, MuyaBar Malik,
Naji Tabet
Completion of the searches: Anna Noel-Storr
Screening of references: David Denton, Rajesh Abraham, Aalya Al-Assaf, John Anderson, MuyaBar Malik, Naji Tabet
Acquisition of data: David Denton, Rajesh Abraham, Aalya Al-Assaf, John Anderson, MuyaBar Malik, Naji Tabet
'Risk of bias' assessments and GRADE-ing: David Denton, Rajesh Abraham, Anne Rutjes, Lee-Yee Chong, Aalya Al-Assaf, John Anderson,
MuyaBar Malik, Naji Tabet
Statistical analysis: David Denton, Rajesh Abraham, Anne Rutjes, Lee-Yee Chong, Aalya Al-Assaf, John Anderson, MuyaBar Malik
Overall interpretation of data: David Denton, Rajesh Abraham, Anne Rutjes, Lee-Yee Chong, Aalya Al-Assaf, John Anderson, MuyaBar Malik,
Naji Tabet
Manuscript preparation: David Denton, Rajesh Abraham, Anne Rutjes, Lee-Yee Chong, Aalya Al-Assaf, John Anderson, MuyaBar Malik, Naji
Tabet
D E C L A R A T I O N S   O F   I N T E R E S T
Denton DA: none known
Abraham RP:none known
Rutjes AWS: none known





Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid life (Protocol)









Cochrane Database of Systematic Reviews
S O U R C E S   O F   S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
This protocol/review was supported by the National Institute for Health Research, via a Cochrane Programme Grant to the Cochrane
Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the authors and do not necessarily
reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid life (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
21
